Vanguard Group
SEEL

Vanguard Group’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Vanguard Group’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,194
Closed -$166K – 4451
2024
Q1 		$166K Sell
2,194
-24
-1% -$3.17K ﹤0.01% 4200
2023
Q4 		$395K Buy
2,218
+871
+65% +$429K ﹤0.01% 4099
2023
Q3 		$952K Buy
1,347
+46
+4% +$197K ﹤0.01% 3849
2023
Q2 		$5.97M Sell
1,301
-5
-0.4% -$17.3K ﹤0.01% 3223
2023
Q1 		$3.47M Hold
1,306
– – ﹤0.01% 3470
2022
Q4 		$3.41M Hold
1,306
– – ﹤0.01% 3466
2022
Q3 		$5.16M Buy
1,306
+23
+2% +$90.4K ﹤0.01% 3307
2022
Q2 		$3.35M Sell
1,283
-189
-13% -$492K ﹤0.01% 3573
2022
Q1 		$4.74M Buy
1,472
+132
+10% +$568K ﹤0.01% 3556
2021
Q4 		$8.39M Sell
1,340
-8
-0.6% -$61.4K ﹤0.01% 3318
2021
Q3 		$12.5M Buy
1,348
+98
+8% +$842K ﹤0.01% 3120
2021
Q2 		$12.7M Buy
1,250
+489
+64% +$8.04M ﹤0.01% 3086
2021
Q1 		$14.6M Buy
761
+32
+4% +$373K ﹤0.01% 2948
2020
Q4 		$4.42M Buy
729
+601
+470% +$2.36M ﹤0.01% 3420
2020
Q3 		$461K Buy
128
+49
+62% +$176K ﹤0.01% 3833
2020
Q2 		$305K Sell
79
-5
-6% -$16.6K ﹤0.01% 3863
2020
Q1 		$158K Buy
84
+22
+35% +$81.8K ﹤0.01% 3896
2019
Q4 		$321K Hold
62
– – ﹤0.01% 3873
2019
Q3 		$220K Hold
62
– – ﹤0.01% 3948
2019
Q2 		$524K Buy
62
+31
+100% +$326K ﹤0.01% 3819
2019
Q1 		$394K Buy
31
+30
+3,000% +$485K ﹤0.01% 3818
2018
Q4 		$33K Sell
1
-1
-50% -$34.7K ﹤0.01% 4098
2018
Q3 		$70K Sell
2
-1
-33% -$36.8K ﹤0.01% 4105
2018
Q2 		$127K Sell
3
-1
-25% -$37.6K ﹤0.01% 4034
2018
Q1 		$189K Buy
4
+1
+33% +$191K ﹤0.01% 3960
2017
Q4 		$541K Hold
3
– – ﹤0.01% 3727
2017
Q3 		$620K Buy
3
+1
+50% +$164K ﹤0.01% 3703
2017
Q2 		$316K Sell
2
-1
-33% -$140K ﹤0.01% 3816
2017
Q1 		$720K Buy
3
+2
+200% +$553K ﹤0.01% 3669
2016
Q4 		$206K Hold
1
– – ﹤0.01% 3883
2016
Q3 		$473K Hold
1
– – ﹤0.01% 3766
2016
Q2 		$604K Hold
1
– – ﹤0.01% 3749
2016
Q1 		$872K Hold
1
– – ﹤0.01% 3636
2015
Q4 		$1.43M Hold
1
– – ﹤0.01% 3515
2015
Q3 		$2.16M Hold
1
– – ﹤0.01% 3342
2015
Q2 		$2.24M Hold
1
– – ﹤0.01% 3359
2015
Q1 		$2.4M Hold
1
– – ﹤0.01% 3324
2014
Q4 		$1.15M Hold
1
– – ﹤0.01% 3484
2014
Q3 		$1.72M Hold
1
– – ﹤0.01% 3325
2014
Q2 		$2.52M Hold
1
– – ﹤0.01% 3161
2014
Q1 		$2.41M Hold
1
– – ﹤0.01% 3139
2013
Q4 		$2.43M Hold
1
– – ﹤0.01% 3112
2013
Q3 		$1.9M Hold
1
– – ﹤0.01% 3154
2013
Q2 		$2.04M Buy
+1
New +$3.11M ﹤0.01% 3059

Other funds holding SEEL

AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CHA
Carmichael Hill & Associates Gaithersburg, Maryland $282M AUM 32.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group's SEEL Position: Q2 2024 in Review

Vanguard Group sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q2 2024, closing a stake of 2,194 shares — an estimated $166K sold.

Vanguard Group first reported a position in SEEL in Q2 2013 and held it in 44 quarters. The position peaked at $14.6M in Q1 2021. 18 funds tracked by Wall St. Rank hold SEEL as of Q2 2024.

  • Vanguard Group reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Vanguard Group sold 2,194 Seelos Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $166K.
  • Vanguard Group first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2013 and held it in 44 quarters.
  • Vanguard Group's Seelos Therapeutics, Inc. Common Stock position peaked at $14.6M in Q1 2021.
  • 18 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.